Sylvie Ryckebusch
Corporate Officer/Principal presso BIOINVENT INTERNATIONAL AB
Patrimonio netto: 28 411 $ in data 31/03/2024
Profilo
Sylvie Ryckebusch currently works at Domain Therapeutics SA, as Non-Executive Director and BioInvent International AB, as Chief Business Officer from 2022.
Dr. Ryckebusch received her doctorate degree from California Institute of Technology and undergraduate degree from the University of Maryland.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 31/12/2022 | 17 870 ( 0.03% ) | 28 411 $ | 31/03/2024 |
Posizioni attive di Sylvie Ryckebusch
| Società | Posizione | Inizio |
|---|---|---|
| BIOINVENT INTERNATIONAL AB | Corporate Officer/Principal | 09/06/2022 |
Domain Therapeutics SA
 Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | Director/Board Member | - |
Formazione di Sylvie Ryckebusch
| California Institute of Technology | Doctorate Degree |
| University of Maryland | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| BIOINVENT INTERNATIONAL AB | Health Technology |
| Aziende private | 1 |
|---|---|
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | Health Technology |
- Borsa valori
- Insiders
- Sylvie Ryckebusch
